Use of mCRP to enhance immune responses

Details Use of mCRP to enhance immune responses Use of mCRP to enhance immune responses

2000-05-09

2001-08-28

Saunders, David (Department: 1644)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C424S184100, C424S277100, C514S002600, C514S885000

Reexamination Certificate

active

06280743

ABSTRACT:

FIELD OF THE INVENTION
The invention is concerned with enhancing immune responses. In particular, it has been discovered that modified C-reactive protein (mCRP) and mutant-mCRP can be used to enhance immune responses to immunogens and to elicit an immune response to haptens.
BACKGROUND OF THE INVENTION
During injury, invasion of pathogens, or other forms of tissue damage, higher vertebrates implement a cascade of biochemical, immune and inflammatory reactions collectively termed the acute phase response. The inflammation results in an increase in blood flow and the delivery of important factors to the affected site. These factors act to limit microbial growth, reduce tissue damage, and aid in the removal of damaged tissue. The acute phase response is a primitive, nonspecific mechanism which reacts quickly prior to the development of the specific processes of humoral and cellular immunity.
C-reactive protein (CRP) has long been recognized as an important acute phase response protein, and its concentration in serum may increase as much as 1,000-fold during the acute phase response. CRP is a pentamer consisting of five identical subunits, each having a molecular weight of about 23,500. The pentameric form of CRP is sometimes referred to as “native CRP.”
In about 1983, another form of CRP was discovered which is referred to as “modified-CRP” or “mCRP.” The formation of mCRP from native CRP involves the dissociation of native CRP into its subunits which also undergo a change in conformation. As a result, mCRP expresses antigenicity which is distinct from that of native CRP (referred to as “neo-CRP antigenicity”), and antibodies are available which can distinguish mCRP from native CRP (see, e.g., U.S. Pat. No. 5,272,258 and Potempa et al.,
Mol. Immunol.,
24, 531-541 (1987)). The conversion of native CRP into mCRP is irreversible (the subunits do not reassemble into native CRP). Kresl et al.,
Int'l J. Biochem. Cell Biol.,
30, 1415-1426 (1998).
It has been reported that mCRP can influence the development of monocyte cytotoxicity, improve the accessory cell function of monocytes, potentiate aggregated IgG-induced phagocytic cell oxidative metabolism, and increase the production of interleukin- 1, prostaglandin E and lipoxygenase products by monocytes. Potempa et al.,
Protides Biol. Fluids,
34, 287-290 (1987); Potempa et al.,
Inflammation,
12, 391-405 (1988); Potempa et al.,
Proc. Amer. Acad. Cancer Res.,
28, 344a (1987); Chu et al.,
Proc. Amer. Acad. Cancer Res.,
28, 344a (1987); Zeller et al.,
Fed. Proc.,
46, 1033a (1987); Chu et al.,
Proc. Amer. Acad. Cancer Res.,
29, 371a (1988). It is also known that mCRP can be used to treat viral infections, bacterial infections, endotoxic shock and cancer. See U.S. Pat. Nos. 5,283,238,5,405,832, 5,474,904, and 5,585,349. It is further known that mCRP stimulates thrombocytopoiesis and the maturation of megakaryocytes and that it can be used to treat thrombocytopenia. See U.S. Pat. No. 5,547,931. Finally, it is known that mCRP binds immune complexes and aggregated immunoglobulin and can, therefore, be used to remove immune complexes and aggregated immunoglobulin from fluids and to quantitate immune complexes. See U.S. Pat. No. 5,593,897. It should be noted that mCRP differs from native CRP in its biological activities. See, e.g., the patents listed above.
SUMMARY OF THE INVENTION
The invention provides a method of enhancing an immune response to an immunogen in an animal. The method comprises administering to the animal an effective amount of the immunogen and an effective amount of a modified C-reactive protein (mCRP) or a mutant-mCRP, as further defined below.
The invention further provides a vaccine comprising an immunogen and an mCRP or a mutant-mCRP in a pharmaceutically-acceptable vehicle. The invention also provides a method of producing this vaccine. The method comprises combining the immunogen and an mCRP or a mutant-mCRP.
The invention further provides a kit for immunizing an animal to an immunogen. The kit may comprise a container holding the immunogen and a container holding an mCRP or a mutant-mCRP. Alternatively, the kit may comprise one container holding both the immunogen and the mCRP or mutant-mCRP.
In addition, the invention provides a method of eliciting an immune response to a hapten in an animal. The method comprises administering to the animal an effective amount of the hapten in association with an effective amount of an mCRP or a mutant-mCRP.
The invention further provides a vaccine comprising a hapten and an mCRP or a mutant-mCRP in a pharmaceutically-acceptable vehicle. The invention also provides a method of producing this vaccine. The method comprises combining the hapten and an mCRP or a mutant-mCRP.
Finally, the invention provides a kit for immunizing an animal to a hapten. The kit comprises a container holding the hapten and the mCRP or the mutant-mCRP.


REFERENCES:
patent: 4857314 (1989-08-01), O'Connor et al.
patent: 5272258 (1993-12-01), Siegel et al.
patent: 5283238 (1994-02-01), Potempa et al.
patent: 5405832 (1995-04-01), Potempa
patent: 5474904 (1995-12-01), Potempa et al.
patent: 5547931 (1996-08-01), Potempa
patent: 5585349 (1996-12-01), Potempa
patent: 5593897 (1997-01-01), Potempa et al.
patent: 5662907 (1997-09-01), Kubo et al.
patent: 5858399 (1999-01-01), Lanza et al.
patent: 5874238 (1999-02-01), Potempa et al.
patent: 5939529 (1999-08-01), Potempa
patent: 6051415 (2000-04-01), Potempa
patent: WO 93/10799 (1993-06-01), None
patent: WO 93/21944 (1993-11-01), None
Bareika et al., “Changes in C-Reactive Protein Levels in Rabbit Sera Following Intraarticular Injection of Chymopapain,” 45th Annual Meeting, Orthopaedic Research Society, Feb. 1-4, 1999, Anaheim, California.
Bray et al.,J. Immunol., 140(12):4271-4278 (1988).
Bray et al.,Clin. Immunol. Newsletter8, pp. 137-140 (1987).
Chu et al.,Proc. Amer. Acad. Cancer Res., 29, 371a (1988).
Chu et al.,Proc. Amer. Acad. Cancer Res., 28, 344a (1987).
Ciliberto et al.,Nucleic Acids Res., 15, 5895 (1987).
Crump et al., “Bacterial Expression of Mutant Human C-Reactive Protein Subunit,” Annual Meeting of the Society for Industrial Microbiology, Research Triangle Park, North Carolina, Aug. 3-9, 1996 (Abstract).
Crump et al., “Bacterial Expression of Mutant Human C-Reactive Protein Subunit” Annual Meeting of the Society for Industrial Microbiology, Research Triangle Park, North Carolina, Aug. 3-9, 1996.
de Beer et al.,J. Immunol. Meth., 50:17-31 (1982).
Diehl et al., “Effects of the Modified Form of C-Reactive Protein on Human Tumor Cells” Cancer Research AMFR Meeting, 1998.
Diehl et al., “Cellular effects of the modified form of C-reactive protein (mCRP) on tumor cells” 17th Int'l Cancer Congress, Rio de Janeiro, Brazil, Aug. 24-28, 1998.
Hu et al.,Biochem., 25, 7834-39 (1986).
Hu et al.,J. Biol. Chem., 263, 1500-1504 (1988).
Kabat et al., “Antiretroviral Activity of a Recombinant Modified C-Reactive Protein” Twenty-First AIDS Clinical Trials Group Meeting, Sheraton Washington Hotel, Washington, D.C., Jul. 27-31, 1996.
Kilpatrick et al.,Immunol. Res., 10:43-53 (1991), Molecular Genetics Structure and Function of C-Reactive Protein.
Kinoshita et al.,Biochemistry, 28:9840-9848 (1989), Elncidation of a Protease Sensitive Site Involved in the Binding of Calcium to C Reactive Protein.
Kolb-Bachofen,Immunobiol, 183:133-145 (1991), A Review of the Biological Properties of C-Reactive Protein.
Kresl et al.,Int'l J. Biochem. Cell Biol., 30, 1415-1426 (1998), Conversion of Native Biogomeric to a Modified Monomeric Form of Human C Reactive Protein.
Kresl et al.,Tumor Biol., 20:72-87 (1999), Inhibition of Mouse Mammory Adronocacinoma Growth & Metastisis in Mice by a Modified Form of C Reactive Protein.
Lei et al.,J. Biol. Chem., 260, 13377-83 (1985), Genomic DNA Sequence for Human C Reactive Protein.
Motie et al.,J. Immunol., 156:4435-4441 (1996), Binding of Model Soluble Immune Completes to Modified C Reactive Protein.
Motie et al.,Drug Metabolism and Disposition, 26(10):977-981 (1998), Bidistribution and Clearance of 125 I Labeled C Reacti

Affiliated with

Also associated with

Rating

Use of mCRP to enhance immune responses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of mCRP to enhance immune responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of mCRP to enhance immune responses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2460142